[Comparative study of three different chemotherapy protocols for advanced non-small-cell lung cancer].
To compare the efficacy and toxicity of three different chemotherapy protocols for advanced non-small-cell lung cancer (NSCLC). The clinical data of 93 cases with advanced NSCLC treated with (1) ifosfamide plus vindesine plus cisplatin (IVP, 31 cases), (2) mitomycin C plus vindesine plus cisplatin (MVP, 30 cases), and (3) cyclophosphamide plus adriamycin plus cisplatin (CAP, 32 cases) were analysed. The response rate was 48.4% in patients treated with IVP, 40.0% in those treated with MVP, and 28.1% in those with CAP, respectively. The major toxic reactions in the three groups were tolerable myelo-suppression and hair loss. IVP and MVP are effective and safe chemotherapeutic protocols for the treatment of advanced NSCLC patients.